产品
编 号：F428224
分子式：C6H15N5
分子量：157.22
分子式：C6H15N5
分子量：157.22
产品类型
规格
价格
是否有货
结构图
CAS No: 692-13-7
产品详情
生物活性：
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
体内研究：
Buformin (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic miceAnimal Model:Female MMTV-erbB-2 transgenic mice
Dosage:7.6?mmol/kg
Administration:Oral administation; 7 days
Result:Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.
体外研究：
Buformin (0-10?mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7?μM and ?98.6?μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively.Buformin (0-3 mM; 48 hours) ?increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells.Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling ?downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
体内研究：
Buformin (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic miceAnimal Model:Female MMTV-erbB-2 transgenic mice
Dosage:7.6?mmol/kg
Administration:Oral administation; 7 days
Result:Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.
体外研究：
Buformin (0-10?mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7?μM and ?98.6?μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively.Buformin (0-3 mM; 48 hours) ?increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells.Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling ?downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备